NuVasive Beats on Both Top and Bottom Lines
NuVasive (NAS: NUVA) reported earnings on April 30. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), NuVasive beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased. Non-GAAP earnings per share grew significantly. GAAP earnings per share stayed the same.
Gross margins contracted, operating margins dropped, net margins expanded.
NuVasive notched revenue of $159.5 million. The 21 analysts polled by S&P Capital IQ hoped for sales of $157.3 million on the same basis. GAAP reported sales were 5.2% higher than the prior-year quarter's $151.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.26. The 21 earnings estimates compiled by S&P Capital IQ predicted $0.22 per share. Non-GAAP EPS of $0.26 for Q1 were 30% higher than the prior-year quarter's $0.20 per share. GAAP EPS of $0.02 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 75.5%, 20 basis points worse than the prior-year quarter. Operating margin was 4.0%, 100 basis points worse than the prior-year quarter. Net margin was 0.5%, 10 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $162.4 million. On the bottom line, the average EPS estimate is $0.25.
Next year's average estimate for revenue is $657.3 million. The average EPS estimate is $1.01.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 168 members out of 187 rating the stock outperform, and 19 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 33 give NuVasive a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on NuVasive is outperform, with an average price target of $21.71.
Is NuVasive the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add NuVasive to My Watchlist.
The article NuVasive Beats on Both Top and Bottom Lines originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.